Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Expands By 224.7%

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 904,700 shares, a growth of 224.7% from the August 31st total of 278,600 shares. Approximately 5.3% of the company’s shares are short sold. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is presently 0.6 days.

Institutional Investors Weigh In On TransCode Therapeutics

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC purchased a new position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of TransCode Therapeutics in a report on Friday, September 6th.

TransCode Therapeutics Stock Performance

RNAZ traded up $0.07 during trading on Wednesday, hitting $0.49. 2,096,975 shares of the company’s stock traded hands, compared to its average volume of 1,189,102. The company’s 50 day simple moving average is $0.32 and its two-hundred day simple moving average is $0.71. TransCode Therapeutics has a 12-month low of $0.22 and a 12-month high of $38.00.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its earnings results on Wednesday, August 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). Research analysts anticipate that TransCode Therapeutics will post -2.06 earnings per share for the current fiscal year.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.